Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ)

CNY 4.11

(0.0%)

Market Cap (In CNY)

12.61 Billion

Revenue (In CNY)

6.12 Billion

Net Income (In CNY)

506.63 Million

Avg. Volume

32.75 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.01-4.87
PE
-
EPS
-
Beta Value
-0.075
ISIN
CNE100000GF1
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Dan Zheng
Employee Count
-
Website
https://www.chasesun.cn
Ipo Date
2009-10-30
Details
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemotherapy, as well as anesthesia drugs and immunomodulators. The company was founded in 1996 and is based in Tianjin, China.